Annual Total Long Term Liabilities
$410.19 M
-$77.38 M-15.87%
December 31, 2023
Summary
- As of February 12, 2025, TVTX annual total long term liabilities is $410.19 million, with the most recent change of -$77.38 million (-15.87%) on December 31, 2023.
- During the last 3 years, TVTX annual total long term liabilities has risen by +$106.63 million (+35.13%).
- TVTX annual total long term liabilities is now -15.87% below its all-time high of $487.57 million, reached on December 31, 2022.
Performance
TVTX Long Term Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Long Term Liabilities
$344.83 M
-$69.88 M-16.85%
September 30, 2024
Summary
- As of February 12, 2025, TVTX quarterly total long term liabilities is $344.83 million, with the most recent change of -$69.88 million (-16.85%) on September 30, 2024.
- Over the past year, TVTX quarterly long term liabilities has dropped by -$65.37 million (-15.94%).
- TVTX quarterly long term liabilities is now -31.14% below its all-time high of $500.79 million, reached on March 31, 2022.
Performance
TVTX Quarterly Long Term Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Long Term Liabilities Formula
Long-Term Liabilities = Long-Term Debt + Deferred Tax Liabilities + Pension Liabilities + Other Long-Term Liabilities
TVTX Long Term Liabilities Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -15.9% | -15.9% |
| 3 y3 years | +35.1% | -29.3% |
| 5 y5 years | +43.3% | -29.3% |
TVTX Long Term Liabilities Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -15.9% | +17.1% | -31.1% | at low |
| 5 y | 5-year | -15.9% | +42.4% | -31.1% | +23.5% |
| alltime | all time | -15.9% | -100.0% | -31.1% | -100.0% |
Travere Therapeutics Long Term Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $344.83 M(-16.9%) |
| Jun 2024 | - | $414.71 M(-0.4%) |
| Mar 2024 | - | $416.25 M(+1.5%) |
| Dec 2023 | $410.19 M(-15.9%) | $410.19 M(-0.8%) |
| Sep 2023 | - | $413.65 M(-14.6%) |
| Jun 2023 | - | $484.23 M(-0.9%) |
| Mar 2023 | - | $488.45 M(+0.2%) |
| Dec 2022 | $487.57 M(+39.1%) | $487.57 M(-1.4%) |
| Sep 2022 | - | $494.51 M(-0.8%) |
| Jun 2022 | - | $498.29 M(-0.5%) |
| Mar 2022 | - | $500.79 M(+42.9%) |
| Dec 2021 | $350.43 M(+15.4%) | $350.43 M(-1.2%) |
| Sep 2021 | - | $354.54 M(+11.7%) |
| Jun 2021 | - | $317.49 M(+0.4%) |
| Mar 2021 | - | $316.34 M(+4.2%) |
| Dec 2020 | $303.57 M(+5.3%) | $303.57 M(-3.7%) |
| Sep 2020 | - | $315.38 M(+8.7%) |
| Jun 2020 | - | $290.12 M(+3.9%) |
| Mar 2020 | - | $279.22 M(-3.1%) |
| Dec 2019 | $288.15 M(+0.7%) | $288.15 M(+3.0%) |
| Sep 2019 | - | $279.84 M(-0.0%) |
| Jun 2019 | - | $279.90 M(+0.7%) |
| Mar 2019 | - | $277.88 M(-2.9%) |
| Dec 2018 | $286.29 M(+102.3%) | $286.29 M(-3.7%) |
| Sep 2018 | - | $297.25 M(+198.3%) |
| Jun 2018 | - | $99.66 M(-31.2%) |
| Mar 2018 | - | $144.79 M(+2.3%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2017 | $141.54 M(+5.4%) | $141.54 M(+7.2%) |
| Sep 2017 | - | $132.09 M(+0.3%) |
| Jun 2017 | - | $131.68 M(-0.9%) |
| Mar 2017 | - | $132.89 M(-1.0%) |
| Dec 2016 | $134.25 M(+7.1%) | $134.25 M(-3.3%) |
| Sep 2016 | - | $138.83 M(-0.5%) |
| Jun 2016 | - | $139.53 M(+15.1%) |
| Mar 2016 | - | $121.25 M(-3.2%) |
| Dec 2015 | $125.31 M(+92.2%) | $125.31 M(+5.6%) |
| Sep 2015 | - | $118.67 M(+16.4%) |
| Jun 2015 | - | $101.98 M(-29.8%) |
| Mar 2015 | - | $145.26 M(+122.8%) |
| Dec 2014 | $65.18 M(+1710.2%) | $65.18 M(-39.1%) |
| Sep 2014 | - | $106.98 M(+0.5%) |
| Jun 2014 | - | $106.48 M(+565.8%) |
| Mar 2014 | - | $15.99 M(+344.2%) |
| Dec 2013 | $3.60 M(>+9900.0%) | $3.60 M(>+9900.0%) |
| Sep 2013 | - | $0.00(0.0%) |
| Jun 2013 | - | $0.00(-100.0%) |
| Mar 2013 | - | $6.96 M(>+9900.0%) |
| Dec 2012 | $0.00(0.0%) | - |
| Nov 2012 | - | $0.00(0.0%) |
| Aug 2012 | - | $0.00(0.0%) |
| May 2012 | - | $0.00(0.0%) |
| Feb 2012 | - | $0.00(0.0%) |
| Feb 2012 | $0.00(0.0%) | - |
| Nov 2011 | - | $0.00(0.0%) |
| Feb 2011 | $0.00 | $0.00 |
FAQ
- What is Travere Therapeutics annual total long term liabilities?
- What is the all time high annual total long term liabilities for Travere Therapeutics?
- What is Travere Therapeutics annual total long term liabilities year-on-year change?
- What is Travere Therapeutics quarterly total long term liabilities?
- What is the all time high quarterly long term liabilities for Travere Therapeutics?
- What is Travere Therapeutics quarterly long term liabilities year-on-year change?
What is Travere Therapeutics annual total long term liabilities?
The current annual total long term liabilities of TVTX is $410.19 M
What is the all time high annual total long term liabilities for Travere Therapeutics?
Travere Therapeutics all-time high annual total long term liabilities is $487.57 M
What is Travere Therapeutics annual total long term liabilities year-on-year change?
Over the past year, TVTX annual total long term liabilities has changed by -$77.38 M (-15.87%)
What is Travere Therapeutics quarterly total long term liabilities?
The current quarterly long term liabilities of TVTX is $344.83 M
What is the all time high quarterly long term liabilities for Travere Therapeutics?
Travere Therapeutics all-time high quarterly total long term liabilities is $500.79 M
What is Travere Therapeutics quarterly long term liabilities year-on-year change?
Over the past year, TVTX quarterly total long term liabilities has changed by -$65.37 M (-15.94%)